Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present bluebird bio, Inc. (NASDAQ: BLUE).

Full DD Report for BLUE

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLUE)

bluebird bio (BLUE) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow
The following slide deck was published by bluebird bio, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:46
Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / U.S. benchmarks closed mostly lower on Thursday, with the Dow Jones remaining in the green, as internet and tech shares slumped. The Dow Jones Industrial Average was up 0.08 percent to close at 25,995.87, while the S&P 500 Index decreased 0...
Source: ACCESSWIRE IA
Date: September, 07 2018 08:00
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
Bluebird bio presents updated data from two studies at SSIEM
Bluebird bio (NASDAQ: BLUE ) announces presentations at SSIEM in Athens. More news on: bluebird bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 05 2018 08:19
bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D(TM) Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM
− Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results – − General Agreement Reached on Regulatory Pathway for Lenti-D in the U.S. and EU – bluebird bio, Inc . (Nasdaq: BLUE) announced updated results from...
Source: Business Wire
Date: September, 05 2018 06:11
bluebird bio to Present at Investor Conferences in September
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Citi 13 th Annual Biotech Conference, Wednesday, September 5, 10:30 a.m. ET at the Four Seasons Boston, Boston, MA Wells Fargo Securit...
Source: Business Wire
Date: August, 29 2018 08:00
Today's Research Reports on Trending Tickers: Exelixis and bluebird bio
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with the U.S. and Mexico. The Dow Jones Industrial Average jumped 1.01 percent to close at 2...
Source: ACCESSWIRE IA
Date: August, 28 2018 08:00
IPO Biotech Preview: Gritstone Oncology
Gritstone Oncology ( GRTS ) is gearing up for an $80 million IPO. It filed an SEC Filing on Thursday. I believe that this is a biotech that could be worth a look as a speculative play. For starters, its technology is an emerging type that many other biotechs are working on known as n...
Source: SeekingAlpha
Date: August, 27 2018 13:03
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma
For quite a while now, we've seen a really remarkable transformation in the field of multiple myeloma management. First, we saw the emergence of new crops of targeted therapies with proteasome inhibitors made by outlets like Amgen ( AMGN ) and Takeda ( TKPYY ), as well as Celgene's ( CELG ) su...
Source: SeekingAlpha
Date: August, 24 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-11102.56104.82105.725100.99846,886
2018-12-10102.23102.15104.9099.15648,889
2018-12-07108.12102.23109.51101.751,024,764
2018-12-06107.62108.85114.3106100.991,228,227
2018-12-04116.86113.65125.36113.641,188,814

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1172,021193,33537.2519Short
2018-12-1069,125131,65052.5066Short
2018-12-07105,772378,97527.9100Cover
2018-12-06132,955478,38027.7928Cover
2018-12-04130,507331,08039.4186Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLUE.


About bluebird bio, Inc. (NASDAQ: BLUE)

Logo for bluebird bio, Inc. (NASDAQ: BLUE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BLUE)

      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 18 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 21 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 21 2018

       

       


      Daily Technical Chart for (NASDAQ: BLUE)

      Daily Technical Chart for (NASDAQ: BLUE)


      Stay tuned for daily updates and more on (NASDAQ: BLUE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BLUE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLUE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BLUE and does not buy, sell, or trade any shares of BLUE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/